Hopes York could become first UK 'dark sky city'
Experts hope York could become the UK's first "dark sky city" as part of a global movement to combat light pollution.
York St John University academics joined astronomers on Tuesday to discuss how methods including the use of warmer, directional street lighting can have an impact in urban areas.
The nearby North York Moors and the Yorkshire Dales have been designated Dark Sky Reserves since 2020, meaning light pollution is particularly low, but the UK is yet to have a city with dark sky status.
Dr Jen Hall, from the university, said: "We believe York has the potential, knowledge and impetus to be the first.
"By coming together, we can protect our night skies for future generations and make York a model for responsible lighting in cities across the UK."
Techniques put forward to reduce light pollution include using warm white LED lighting, switching lights off at times they're not required and changing angles to ensure lights point down towards the ground.
The university said it had introduced several of these measures on its main campus, with hopes the project could widen across York.
Dr Hall, associate professor of tourism and events, told BBC Radio York it would be a "huge challenge, but not an insurmountable one".
Mike Hawtin, dark skies conservation lead at the North York Moors National Park Authority, said reducing light pollution was key for protecting nocturnal biodiversity and the environment more broadly.
"Light pollution is easy to fix, it saves us money and reduces carbon emissions," he said.
"The discussion is never ever about banning the light we all need for a wide range of reasons - it's about sensitive, responsible use, to light only what we need, only when we need it and at a level suitable to that need."
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
Festival to celebrate 'inky skies and sparkling stars'
Dark Skies: Leaders of unique reserve issue plea
More streetlights to be turned off or dimmed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in HTT mRNA in healthy volunteers The SKY-0515 Phase 1 trial in patients with Huntington's disease reached full enrollment ahead of schedule BOSTON, June 18, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced that the first patient has been dosed in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an investigational oral RNA splicing modulator for the treatment of Huntington's disease (HD). SKY-0515 is designed to reduce the production of both HTT and PMS1 proteins—two key drivers of HD pathology. In a Phase 1 study in healthy volunteers, SKY-0515 demonstrated dose-dependent HTT mRNA reduction, achieving an average of 72% lowering at the highest dose tested. The compound was generally well tolerated across all doses. Additionally, the Company's Phase 1 trial in HD patients, which began in January 2025, completed enrollment ahead of schedule in March 2025. "Dosing the first patient in our FALCON-HD trial marks a significant milestone in our mission to develop a disease-modifying therapy for Huntington's patients," said Bill Haney, Founder and Chief Executive Officer of Skyhawk Therapeutics. "Building on our compelling Phase 1 data, we are eager to assess SKY-0515's potential to make a meaningful difference in the lives of patients affected by this devastating condition." FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial includes multiple sites across Australia and New Zealand. The initial dosing took place at Flinders Medical Centre in Adelaide, Australia. "We are pleased to participate in this important clinical trial and to have dosed the first patient here at Flinders," said Dr. Karyn Boundy, FRACP, Neurologist, Principal Investigator at Flinders Medical Centre. "Given the lack of approved disease-modifying treatments for Huntington's disease, we are hopeful that SKY-0515 could offer a new therapeutic option for patients." "As Skyhawk kicks off their Phase 2/3 FALCON-HD trial in Australia and New Zealand, the international Huntington's community looks forward to expansion worldwide," said Ed Wild, professor of neurology at the University College London. "SKY-0515's unique ability to reduce both HTT and PMS1 could meaningfully enhance therapeutic impact beyond that of lowering HTT alone." About the FALCON-HD TrialFALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early Stage 3 HD. The trial plans to enroll 120 subjects across 10 sites in Australia and New Zealand. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels, or placebo, for a treatment period of at least 12 months. The trial aims to assess the potential of SKY-0515 to modulate RNA splicing and reduce the production of huntingtin (HTT) and PMS1 proteins, which are implicated in the pathology of Huntington's disease. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at and About SKY-0515SKY-0515 is an orally administered small molecule RNA splicing modulator developed through Skyhawk's proprietary platform. It is designed to reduce production of both huntingtin (HTT) and PMS1 proteins, two key contributors to Huntington's disease. SKY-0515 has shown robust, dose-dependent HTT mRNA reduction—up to 72%—in healthy volunteer studies, with favorable safety and tolerability. SKY-0515 is currently being evaluated in a Phase 2/3 clinical trial. About Skyhawk TherapeuticsSkyhawk Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapies designed to modulate critical RNA targets and revolutionize patient treatment for some of the world's most intractable diseases. Skyhawk's discovery expertise is rooted in its proprietary drug discovery platform, which assesses, identifies, and tests RNA splicing targets and small molecules across a broad range of therapeutic areas and disease states. Skyhawk has built collaborations with multiple pharma partners that leverage Skyhawk's novel platform across disease areas including neurodegenerative disease, autoimmune disease, and oncology. For more information visit Skyhawk ContactsKyle Dow, VP Corporate Logo - View original content: SOURCE Skyhawk Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Business Wire
NMDP's ACCESS Trial Results Published in Journal of Clinical Oncology, Demonstrating Strong Outcomes with Mismatched Unrelated Donors in Adult Stem Cell Transplantation
MINNEAPOLIS--(BUSINESS WIRE)--Results from the ACCESS (Allogeneic Cell Transplantation Clinical Evaluation of Stem Cell Sources) study, a multicenter Phase II clinical trial sponsored by NMDP SM, a global nonprofit leader in cell therapy, and conducted by its collaborative research program, CIBMTR® (Center for International Blood and Marrow Transplant Research®), were published in the peer-reviewed Journal of Clinical Oncology. The results demonstrate that post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis enables safe and effective hematopoietic cell transplantation (HCT) from mismatched unrelated donors (MMUD), significantly expanding access to curative therapy for patients with blood cancers. Evaluating outcomes in two conditioning intensity groups—myeloablative (MAC) and reduced-intensity/nonmyeloablative (RIC/NMA)—the study found there was no significant difference in overall survival (OS) between patients with 7/8 HLA-matched donors and those with <7/8 matches, supporting broader donor eligibility. The one-year OS was 83.8% for MAC and 78.6% for RIC/NMA recipients. These outcomes were comparable to, or better than, historical 8/8 matched donor benchmarks (75%). 'These study results are a major step forward in making allogeneic peripheral blood stem cell transplantation more accessible for all patients who need a lifesaving procedure,' said Monzr M. Al Malki, M.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope and ACCESS study co-chair. 'By demonstrating that mismatched unrelated donors can be used safely and effectively, we are opening the door to curative therapy for patients who historically had limited or no donor options. The findings published also lay the groundwork for future Phase III trials comparing MMUD transplantation to other alternative donor strategies.' The trial enrolled 145 adult patients with high-risk hematologic malignancies across 21 U.S. transplant centers, with 59% self-identifying as members of underrepresented racial or ethnic groups. Participants received peripheral blood stem cell (PBSC) grafts from MMUDs and were treated with a standardized PTCy-based GVHD prophylaxis regimen. Low rates of severe GVHD were also observed, with grade III-IV acute GVHD at six months occurring in only 8% (MAC) and 10% (RIC/NMA) and severe chronic GVHD at 12 months in only 3% (MAC) and 4% (RIC/NMA) of patients. The pool of study participants included a high representation of socially vulnerable populations, with many patients reporting financial hardship and reduced physical function at baseline. NMDP-led Donor for All research Historically, finding an available matched, unrelated donor on international registries has been limited for patients with ethnically diverse ancestry— from as low as 29% for Black or African American patients and 48% for Latino and Hispanic patients versus 79% for non-Hispanic White patients. NMDP's network of transplant centers, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established HCT science. To improve outcomes, NMDP is sponsoring a series of clinical trials studying the use of PTCy GVHD prophylaxis in MMUD HCT (patients matched at 4/8 to 7/8 alleles). ACCESS builds upon findings from the first Donor for All trial, the groundbreaking NMDP-sponsored 15-MMUD study, which showed that PTCy was effective in decreasing risk for GVHD in adults with hematologic malignancies receiving bone marrow transplants from MMUDs. ACCESS is closed to further enrollment, with pediatric results forthcoming next year. The OPTIMIZE trial is now enrolling and evaluating whether a reduced dose of PTCy will safely and effectively prevent GVHD while reducing infection risk in patients with hematologic malignancies receiving PBSC HCT from MMUDs. The ACCELERATE trial will open to accrual this summer to further reduce the risk of GVHD and other post-transplant complications in patients. 'Our Donor for All research is transforming cell therapy as well as redefining donor eligibility and transplant accessibility – helping close the donor gap and extend curative therapies to every patient who needs a life-saving transplant,' Steven Devine, MD, chief medical officer, NMDP, and senior scientific director, CIBMTR, and a senior author of the study, added. About CIBMTR® CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a nonprofit research collaboration between NMDP SM, in Minneapolis, and the Medical College of Wisconsin®, in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 675,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at About NMDP SM At NMDP SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world's most diverse registry and our extensive network of transplant partners, physicians and caregivers, we're expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at
Associated Press
4 days ago
- Associated Press
NMDP's ACCESS Trial Results Published in Journal of Clinical Oncology, Demonstrating Strong Outcomes with Mismatched Unrelated Donors in Adult Stem Cell Transplantation
MINNEAPOLIS--(BUSINESS WIRE)--Jun 17, 2025-- Results from the ACCESS (Allogeneic Cell Transplantation Clinical Evaluation of Stem Cell Sources) study, a multicenter Phase II clinical trial sponsored by NMDP SM, a global nonprofit leader in cell therapy, and conducted by its collaborative research program, CIBMTR® (Center for International Blood and Marrow Transplant Research®), were published in the peer-reviewed Journal of Clinical Oncology. The results demonstrate that post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis enables safe and effective hematopoietic cell transplantation (HCT) from mismatched unrelated donors (MMUD), significantly expanding access to curative therapy for patients with blood cancers. Evaluating outcomes in two conditioning intensity groups—myeloablative (MAC) and reduced-intensity/nonmyeloablative (RIC/NMA)—the study found there was no significant difference in overall survival (OS) between patients with 7/8 HLA-matched donors and those with <7/8 matches, supporting broader donor eligibility. The one-year OS was 83.8% for MAC and 78.6% for RIC/NMA recipients. These outcomes were comparable to, or better than, historical 8/8 matched donor benchmarks (75%). 'These study results are a major step forward in making allogeneic peripheral blood stem cell transplantation more accessible for all patients who need a lifesaving procedure,' said Monzr M. Al Malki, M.D., Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope and ACCESS study co-chair. 'By demonstrating that mismatched unrelated donors can be used safely and effectively, we are opening the door to curative therapy for patients who historically had limited or no donor options. The findings published also lay the groundwork for future Phase III trials comparing MMUD transplantation to other alternative donor strategies.' The trial enrolled 145 adult patients with high-risk hematologic malignancies across 21 U.S. transplant centers, with 59% self-identifying as members of underrepresented racial or ethnic groups. Participants received peripheral blood stem cell (PBSC) grafts from MMUDs and were treated with a standardized PTCy-based GVHD prophylaxis regimen. Low rates of severe GVHD were also observed, with grade III-IV acute GVHD at six months occurring in only 8% (MAC) and 10% (RIC/NMA) and severe chronic GVHD at 12 months in only 3% (MAC) and 4% (RIC/NMA) of patients. The pool of study participants included a high representation of socially vulnerable populations, with many patients reporting financial hardship and reduced physical function at baseline. NMDP-led Donor for All research Historically, finding an available matched, unrelated donor on international registries has been limited for patients with ethnically diverse ancestry— from as low as 29% for Black or African American patients and 48% for Latino and Hispanic patients versus 79% for non-Hispanic White patients. NMDP's network of transplant centers, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established HCT science. To improve outcomes, NMDP is sponsoring a series of clinical trials studying the use of PTCy GVHD prophylaxis in MMUD HCT (patients matched at 4/8 to 7/8 alleles). 'Our Donor for All research is transforming cell therapy as well as redefining donor eligibility and transplant accessibility – helping close the donor gap and extend curative therapies to every patient who needs a life-saving transplant,' Steven Devine, MD, chief medical officer, NMDP, and senior scientific director, CIBMTR, and a senior author of the study, added. About CIBMTR® CIBMTR® (Center for International Blood and Marrow Transplant Research®) is a nonprofit research collaboration between NMDP SM, in Minneapolis, and the Medical College of Wisconsin®, in Milwaukee. CIBMTR collaborates with the global scientific community to increase survival and enrich quality of life for patients. CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of centers, and a unique database of long-term clinical data for more than 675,000 people who have received hematopoietic cell transplantation and other cellular therapies. Learn more at About NMDP SM At NMDP SM, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world's most diverse registry and our extensive network of transplant partners, physicians and caregivers, we're expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more at View source version on CONTACT: Media contact: Jess Ayers [email protected] KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS GENERAL HEALTH CLINICAL TRIALS RESEARCH SCIENCE SOURCE: NMDP Copyright Business Wire 2025. PUB: 06/17/2025 10:14 AM/DISC: 06/17/2025 10:14 AM
